Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Atgenomix is a bioinformatics company specializing in cloud-native platforms for large-scale genomic data analysis and precision medicine. The company's core technology, SeqsLab, utilizes distributed computing and hardware acceleration to optimize Next-Generation Sequencing (NGS) workflows, significantly reducing processing times for clinical and research applications. In January 2024, Atgenomix was acquired by Oxford Nanopore Technologies to integrate its high-performance computing and data management capabilities into the Oxford Nanopore sequencing ecosystem. This integration aims to provide a seamless, end-to-end solution from real-time sequencing to clinical-grade data interpretation and storage.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Atgenomix.